Atai Beckley (ATAI) Stock Price, News & Analysis

Company Overview

Atai Beckley is a clinical-stage biotechnology company developing novel therapies for mental health disorders through a decentralized model of wholly owned subsidiaries and strategic collaborations. Founded in 2018 by entrepreneur Christian Angermayer, Atai Beckley focuses on addressing unmet needs in conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders and attention-deficit/hyperactivity disorder (ADHD). The company’s approach combines psychedelic and non-psychedelic molecules alongside digital therapeutics to create differentiated treatment paradigms.

The Atai Beckley pipeline features multiple proprietary programs, including a deuterated psilocybin analog designed for enhanced stability and tolerability, an intravenous synthetic DMT administered via a patented delivery system, and novel ketamine derivatives engineered to minimize dissociative side effects. In addition, Atai Beckley has launched subsidiaries such as Perception Neuroscience, which focuses on nasal DMT delivery, and DemeRx, which develops treatments for addiction. These platform technologies are supplemented by biomarker development and patient-reported outcome tools aimed at optimizing clinical trial design and therapeutic impact.

Headquartered in Berlin, Germany, with research and development operations in North America and Europe, Atai Beckley conducts global clinical trials across multiple geographies. The company entered the public markets in 2021 through a special purpose acquisition company (SPAC) merger, providing capital to advance lead programs into late-stage studies. Atai Beckley leverages partnerships with academic institutions, contract research organizations and regulatory experts to streamline development pathways and support potential approvals in major markets.

Governed by founder Christian Angermayer and a leadership team drawn from established biopharma and academic backgrounds, Atai Beckley emphasizes robust clinical evidence and regulatory compliance. The company’s scientific advisory board includes experts in psychiatry, neurology and drug delivery, reinforcing its commitment to pioneering safe, effective treatments that could transform the standard of care for patients with chronic mental health conditions.

Key Stats

• Today's Range: $3.95 to $4.23
• 50-Day Range: $3.35 to $4.90
• 52-Week Range: $1.29 to $6.75
• Volume: 4.56 million shs
• Average Volume: 5.27 million shs
• Market Capitalization: $1.47 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.63
• Consensus Rating: Buy

Atai Beckley Stock Analysis - MarketRank™

Atai Beckley scored higher than 61% of companies evaluated by MarketBeat, and ranked 310th out of 854 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Atai Beckley has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Atai Beckley has a consensus price target of $14.63, representing about 267.9% upside from its current price of $3.98.

Amount of Analyst Coverage

Atai Beckley has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Atai Beckley are expected to decrease in the coming year, from ($0.48) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atai Beckley is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atai Beckley is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atai Beckley has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.80% of the float of Atai Beckley has been sold short.

Short Interest Ratio / Days to Cover

Atai Beckley has a short interest ratio ("days to cover") of 8.82.

Change versus previous month

Short interest in Atai Beckley has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atai Beckley does not currently pay a dividend.

Dividend Growth

Atai Beckley does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Atai Beckley has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Atai Beckley this week, compared to 6 articles on an average week.

Search Interest

68 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 209% compared to the previous 30 days.

MarketBeat Follows

12 people have added Atai Beckley to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Atai Beckley insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $212,895.00 in company stock.

Percentage Held by Insiders

26.80% of the stock of Atai Beckley is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

28.41% of the stock of Atai Beckley is held by institutions.

ATAI Stock Analysis - Frequently Asked Questions

How have ATAI shares performed this year?

Atai Beckley's stock was trading at $4.09 at the beginning of the year. Since then, ATAI shares have decreased by 2.8% and is now trading at $3.9750.

How were Atai Beckley's earnings last quarter?

Atai Beckley N.V. (NASDAQ:ATAI) announced its quarterly earnings data on Saturday, March, 7th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.50 million. Atai Beckley had a negative trailing twelve-month return on equity of 87.51% and a negative net margin of 16,142.01%.

When did Atai Beckley IPO?

Atai Beckley (ATAI) raised $210 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 15,000,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are Atai Beckley's major shareholders?

Top institutional shareholders of Atai Beckley include Candriam S.C.A. (0.84%), AdvisorShares Investments LLC (0.15%), Sumitomo Mitsui Trust Group Inc. (0.15%) and OP Asset Management Ltd (0.12%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar, Srinivas Rao and Kevin James Craig.
View institutional ownership trends.

How do I buy shares of Atai Beckley?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Atai Beckley own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Beckley investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 3/07/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATAI
• CIK: 1420529
• Web: www.ataibeckley.com
• Phone: 31 20 793 2536
• Fax: N/A
• Employees: 80
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Atai Beckley: $14.63
• High Price Target: $25.00
• Low Price Target: $5.00
• Potential Upside/Downside: +265.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$660.05 million
• Net Margins: -16,142.01%
• Pretax Margin: -5,106.46%
• Return on Equity: -87.51%
• Return on Assets: -63.88%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 7.90
• Quick Ratio: 7.90

Sales & Book Value

• Annual Sales: $4.09 million
• Price / Sales: 358.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 5.80

Miscellaneous

• Outstanding Shares: 366,920,000
• Free Float: 268,583,000
• Market Cap: $1.47 billion
• Optionable: Optionable
• Beta: 1.59